Ole Miss & the NIDA Cannabis Farm — 1968–2021

Last verified: May 2026

The 57-Year Exclusive Contract

From 1968 until 2021, the University of Mississippi was the only federally licensed cannabis grower in the United States. The contract was held with the National Institute on Drug Abuse (NIDA) and operated through the National Center for Natural Products Research (NCNPR), with the cannabis program led by Dr. Mahmoud ElSohly. NCNPR’s overall director is Dr. Ikhlas Khan.

The 57-year exclusive contract gave Ole Miss a unique position in U.S. cannabis research: every federally-funded cannabis study, every DEA-approved clinical trial, every academic researcher requesting NIDA cannabis material received it from the Ole Miss farm. The arrangement defined the contours of U.S. academic cannabis research for nearly six decades.

The Research Output

According to the University of Mississippi Office of News (January 2022): "Of the 50 new cannabinoids discovered between 2005 and 2015, 43 can be attributed to Ole Miss researchers." NCNPR’s cannabis program has been the primary U.S. academic source for:

• Cannabinoid identification and structural characterization.
• Standardized analytical methods for THC and CBD quantification.
• Pharmacological studies of synthetic cannabinoids.
• Quality-control reference standards for cannabis-product testing.
• Educational materials for clinical researchers and regulatory bodies.

The 2021 End of Exclusivity — And the 2028 Wind-Down

In 2021 the DEA began licensing additional federal cannabis cultivators, ending Ole Miss’s exclusive contract. The remaining NIDA contract with Ole Miss continues through 2028, after which the federal cannabis-research supply chain will be fully diversified across multiple licensed cultivators (including Biopharmaceutical Research Company in California, Royal Emerald Pharmaceuticals, and others).

The end of Ole Miss’s exclusive position reflects broader U.S. cannabis-policy normalization: as state programs proliferated and academic interest expanded, maintaining a single federal cultivator became politically and scientifically untenable.

The National Center for Cannabis Research and Education (NCCRE)

In 2022, Ole Miss established the National Center for Cannabis Research and Education (NCCRE) within the UM School of Pharmacy. NCCRE is the institutional successor to the NIDA-only cultivation contract, expanding Ole Miss’s research scope into:

• Clinical cannabis research and trials.
• Cannabis policy education for clinicians, regulators, and the public.
• Cannabis-quality and -safety standards development.
• Industry collaborations on product formulation and analytical methods.

NCCRE complements the still-active basic research at NCNPR. Together, the two centers position Ole Miss to remain a leading U.S. academic cannabis research institution even as the cultivation-supply landscape diversifies.

The R3CR Partnership

The Resource Center for Cannabis and Cannabinoid Research (R3CR) is a partnership between Ole Miss, Washington State University, and the U.S. Pharmacopoeia, supported by NIH/NCCIH (National Center for Complementary and Integrative Health). R3CR provides shared research infrastructure for the broader academic cannabis-research community.

What This Means for Mississippi Cannabis Policy

Ole Miss’s research footprint creates an unusual political asset for Mississippi cannabis policy: the state is, in academic and federal terms, a leading center for legitimate cannabis science. This stands in some tension with Mississippi’s deeply restrictive medical program and its outright prohibition on recreational use. Specifically:

• Mississippi-licensed Ole Miss researchers can study cannabis pharmacology with federal authorization.
• The same cannabis cannot be lawfully home-grown by a Mississippi MMCP cardholder.
• The same cannabis exceeds Mississippi’s 30% THC flower / 60% concentrate caps in the dispensary marketplace.
• Ole Miss faculty researching cannabis are not exempt from federal drug-testing requirements as federal-grant recipients.

The structural disconnect between research authority and clinical/recreational access is one of the curiosities of Mississippi cannabis policy.

Harper Grace’s Law — The 2014 Predecessor

Mississippi’s cannabis policy did not move from prohibition directly to SB 2095 in 2022. There was an interim step: Harper Grace’s Law, the 2014 statute that allowed UMMC (the University of Mississippi Medical Center in Jackson) to conduct CBD research for severe pediatric epilepsy. The law preceded the broader medical cannabis framework by eight years and remains the framework under which UMMC’s clinical CBD trials operate.

UMMC has indicated planning for a THC-inclusive clinical trial framework once federal rescheduling completes. The interaction between UMMC’s clinical research, Ole Miss’s NCNPR/NCCRE basic research, and the broader MMCP patient program creates a research-to-practice pipeline that few other state medical programs have.

The Trump Executive Order 14370 Tailwind

President Trump’s December 18, 2025 Executive Order 14370 (Increasing Medical Marijuana and Cannabidiol Research) directed the U.S. Attorney General to "take all necessary steps to complete the rulemaking process related to rescheduling marijuana to Schedule III of the CSA." If completed, the rescheduling would substantially expand Ole Miss’s research authority and reduce regulatory friction for cannabis clinical research generally. The rescheduling rule had not been finalized as of April 2026, but UMMC’s planned THC clinical trial framework is positioned to launch upon completion.

Reading More

• National Center for Natural Products Research (NCNPR)
• National Center for Cannabis Research and Education (NCCRE)